“The existing condition has exposed some structural weaknesses inside the EU’s medicines offer chain and a high dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides stated. She proposed that offer chain challenges be addressed in an EU pharmaceutical technique predicted to be released by the end of the 12 months.L